Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-14, Stock:LLY, The news for the past five days is as follows:
2018-09-07: NEWS1: AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status.NEWS2: AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status.NEWS3: AstraZeneca&apos;s Asthma Drug Gets Breakthrough Therapy Status.NEWS4: Lilly, Teva, Pfizer & Others Await FDA Decisions in September.
2018-09-10: NEWS1: Health Care Sector Update for 09/10/2018: MYOK, ACAD, MRK, FOLD, LLY.NEWS2: Health Care Sector Update for 09/10/2018: MYOK, ACAD, MRK, FOLD, LLY.NEWS3: Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis.NEWS4: Health Care Sector Update for 09/10/2018: ACAD,MRK,FOLD.NEWS5: Health Care Sector Update for 09/10/2018: ACAD,MRK,FOLD.NEWS6: Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD.NEWS7: Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD.NEWS8: Lilly to Showcase New Data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, Furthering Innovation for Patients with Complex Dermatological Conditions.NEWS9: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS10: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS11: Glaxo&apos;s Nucala Suffers Regulatory Setback, Gets CRL for COPD.NEWS12: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS13: Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis.
2018-09-11: NEWS1: Pfizer Announces Results for JAVELIN Renal 101 Study.NEWS2: Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe.NEWS3: Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe.
2018-09-12: NEWS1: Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug.NEWS2: Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug.NEWS3: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.NEWS4: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.NEWS5: Merck's Antibacterial Drug Succeeds in Label Expansion Study.NEWS6: Merck's Antibacterial Drug Succeeds in Label Expansion Study.NEWS7: Incyte, Foundation Medicine Partner for Companion Diagnostics.NEWS8: Incyte, Foundation Medicine Partner for Companion Diagnostics.NEWS9: Merck&apos;s Antibacterial Drug Succeeds in Label Expansion Study.NEWS10: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.NEWS11: Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug.NEWS12: Incyte, Foundation Medicine Partner for Companion Diagnostics.NEWS13: NCCN and Lilly Support Quality Improvements for Gastric Cancer Care.NEWS14: Eli Lilly To Present At Morgan Stanley Conference; Webcast At 1:40 PM ET.NEWS15: Eli Lilly To Present At Morgan Stanley Conference; Webcast At 1:40 PM ET.
2018-09-13: NEWS1: New Lilly Diabetes Center of Excellence Established at the Indiana Bioscience Research Institute.NEWS2: PJP, PFE, MRK, LLY: ETF Outflow Alert.NEWS3: PJP, PFE, MRK, LLY: ETF Outflow Alert.NEWS4: Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?.NEWS5: Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?.NEWS6: Why Eli Lilly (LLY) is a Great Dividend Stock.NEWS7: Why Eli Lilly (LLY) is a Great Dividend Stock.NEWS8: Why Eli Lilly (LLY) is a Great Dividend Stock.NEWS9: See what the IHS Markit Score report has to say about Eli Lilly And Co..

Answer: Decrease